An In-Depth Analysis of Ichor Medical Systems' TriGrid Electroporation Platform

Executive Summary

This report provides a comprehensive analysis of Ichor Medical Systems’ TriGrid® Delivery System. TriGrid is a proprietary platform technology. It is designed to enhance the clinical efficacy of nucleic acid-based therapeutics.

The TriGrid system is a critical enabling technology that solves the long-standing challenge of low in vivo potency. This issue is associated with the direct administration of DNA and RNA drugs. The system’s core innovation translates the scientific principle of electroporation into a clinically viable medical device. It achieves this through sophisticated automation and integration. This process converts a complex laboratory procedure into a standardized, reproducible application.

Key Findings

Technological Innovation: TriGrid’s breakthrough is its integrated, single-button system. It automates the co-localized delivery of a nucleic acid agent and a controlled electrical pulse. This ensures consistency and minimizes operator variability.⁹, ¹⁶, ⁹⁹
Strategic Validation: The 2014 Collaboration and License Agreement with Pfizer Inc. served as a pivotal validation of the technology. The agreement highlighted its importance for enabling DNA-based immuno-oncology programs.²², ⁴⁵, ¹¹⁷ The subsequent industry-wide pivot to mRNA and lipid nanoparticle (LNP) technologies explains the collaboration’s outcome. It does not discredit the TriGrid platform itself.³², ³⁵, ⁴³, ⁴⁶, ⁶⁴
Clinical Performance: Clinical trial data provides strong evidence of performance. Data from the Scancell Holdings plc partnership for the SCIB1 melanoma vaccine is particularly notable. It demonstrates that TriGrid effectively and safely delivers its payload. This leads to potent, clinically meaningful immune responses with a tolerable side effect profile.¹⁹, ⁵⁴, ⁹¹
Market Position: Ichor operates as a specialized technology provider. It exists in a competitive landscape that includes other electroporation systems (e.g., Inovio’s CELLECTRA®). The landscape also includes alternative delivery modalities like LNPs and viral vectors.⁹ Ichor’s success is intrinsically linked to the clinical success of its partners’ therapeutic candidates.
Conclusion: The TriGrid platform is a mature, clinically-validated technology. It addresses a persistent industry challenge. The technology faces risks from partner pipeline failures and technological competition. However, the expanding nucleic acid therapeutics market presents a significant opportunity. Future assessments should focus on the scientific merit of its partners’ pipelines. They should also analyze the competitive positioning of electroporation within specific disease indications.

I. Strategic Overview

This report provides an exhaustive analysis of Ichor Medical Systems’ TriGrid® Delivery System. TriGrid is a proprietary platform technology. Its purpose is to enhance the clinical efficacy of nucleic acid-based therapeutics.

The central finding is that TriGrid is a critical enabling technology, not a therapeutic agent in itself. Its primary function is to solve the long-standing challenge of low in vivo potency. This problem is associated with the direct administration of “naked” DNA and RNA drugs.

The fundamental science of electroporation has been established for decades. The core innovation of the TriGrid platform lies in its successful translation of this scientific principle. It has become a clinically and commercially viable medical device through sophisticated automation, integration, and engineering. This process converted a complex, operator-dependent laboratory procedure into a standardized, reproducible, push-button application suitable for widespread clinical use.

The 2014 Collaboration and License Agreement with Pfizer Inc. represents a pivotal validation event for Ichor. It signaled a clear recognition by a major pharmaceutical corporation of the need for an advanced delivery solution. This solution was to support its then-nascent pipeline of DNA-based immuno-oncology candidates. The subsequent evolution of Pfizer’s own pipeline offers a crucial narrative. Specifically, its highly successful pivot to messenger RNA (mRNA) vaccines delivered via lipid nanoparticles (LNPs) highlights the dynamic field of nucleic acid delivery.

Currently, the TriGrid platform stands as a clinically validated system. Data from multiple clinical trials conducted by its partners support its performance and safety profile. However, its ultimate commercial success is intrinsically linked to the clinical and regulatory success of the therapeutic candidates it delivers.

Consequently, the technology faces several risks. These include risks associated with partner pipeline failures and intense competition from alternative delivery modalities, most notably LNPs. Conversely, the unabated expansion of the broader nucleic acid therapeutics market presents a significant and growing opportunity. This positions TriGrid as a proven solution for a persistent industry challenge.

This report will deconstruct the technology and analyze its market position. It will also dissect its key strategic partnerships and provide a critical assessment of its performance, risks, and future outlook.

II. The TriGrid Delivery System: A Technological Deep Dive

This section details the scientific foundations of the TriGrid system. It also explains its key engineering innovations and architectural components.

A. Foundations: The Science of In Vivo Electroporation

The TriGrid system relies on the biophysical phenomenon of electroporation, also known as electropermeabilization. This process involves applying brief, controlled, high-amplitude electrical field pulses to a target tissue, such as skeletal muscle or skin.⁹, ¹¹

Cell membranes consist of a phospholipid bilayer. They act as natural electrical capacitors and are typically impermeable to large, charged molecules like nucleic acids.⁴, ⁵ When an external electric field exceeds the membrane’s dielectric strength, it induces a temporary change in the transmembrane potential. This change leads to the repulsion and dislocation of phospholipids.², ⁵ The result is the formation of transient, nanoscale aqueous pores in the cell membrane.³, ⁵, ⁷, ¹²

Visual Aid: The Electroporation Mechanism

A simplified, step-by-step illustration of the process:

Initial State: A cell with an intact membrane is surrounded by nucleic acid molecules (e.g., DNA plasmids). The molecules cannot pass through the membrane.
Electric Pulse Application: Electrodes apply a controlled, high-voltage electrical pulse to the tissue.
Pore Formation: The electric field temporarily destabilizes the membrane, creating transient aqueous pores.
Nucleic Acid Entry: Driven by the electric field, the charged DNA molecules move from the exterior into the cell’s cytoplasm through these pores.³, ⁶⁶, ⁶⁷
Membrane Resealing: After the pulse ceases, the cell membrane naturally reseals. This traps the nucleic acid molecules inside, where they can be transcribed and translated.

During this state of increased permeability, molecules can be driven into the cytoplasm.³, ⁵ For nucleic acid-based drugs, this dramatically increases the efficiency of intracellular uptake.⁹ Once inside, the cell’s own machinery can transcribe and translate the DNA or RNA to produce a target protein.¹, ⁹ After the electrical pulse ceases, the cell membrane naturally reseals, restoring its integrity. Cell viability remains largely unaffected if the electrical parameters are optimized for reversible electroporation.⁵, ⁹

This mechanism directly addresses the foundational “potency problem” of nucleic acid therapeutics. For decades, a major obstacle for DNA and RNA vaccines was their poor efficacy when administered via conventional injection.⁹, ⁶⁸ This simple method results in minimal uptake of genetic material, leading to low antigen expression and a suboptimal immune response.⁹, ¹³

Non-clinical studies consistently show that electroporation-mediated delivery can increase antigen expression and subsequent immune responses by 10 to 1,000 times compared to conventional injection alone.⁹ This dramatic enhancement in potency is the scientific bedrock of the TriGrid technology. The history of electroporation dates back to the 1960s and 1970s, with the first in vivo gene electroporation described in 1991.¹, ³, ¹¹, ¹², ⁶², ⁶⁹

B. TriGrid’s Innovation: Overcoming Prior Electroporation Challenges

The question of why a technology like TriGrid did not emerge sooner is not about a lack of scientific understanding. Instead, it relates to the significant engineering and procedural hurdles of translating electroporation into a consistent clinical application.

A commercially viable therapeutic product requires standardized and reproducible administration. Early electroporation methods were complex laboratory setups. They were highly dependent on operator skill, which introduced unacceptable variability in critical parameters like electrode placement and injection timing.⁷⁰

Ichor Medical Systems’ key breakthrough was developing a sophisticated, engineered solution to this clinical delivery problem.

The core innovation of the TriGrid system is its integration and automation of the entire procedure into a single, user-independent device.⁹

The system automatically deploys its electrode array and administers the biologic agent at the touch of a single button.¹⁴, ¹⁵ This patented design precisely controls the site, rate, and timing of the nucleic acid administration relative to the electroporation pulses.⁹, ¹⁶ It ensures the critical co-localization of the electric field with the drug, guaranteeing a consistent and reproducible application every time.⁹, ¹⁴, ¹⁵

This transition from a scientific technique to an engineered product is TriGrid’s primary value proposition. Ichor’s success came from recognizing that commercialization required solving procedural and quality control challenges. This focus on biomedical engineering and human factors design, protected by a strong intellectual property portfolio, distinguished the TriGrid system.⁹, ¹⁶

C. System Architecture and Evolution

The TriGrid Delivery System is a multi-component platform. It is designed for flexibility and scalability from early-phase clinical studies to commercial deployment.⁹, ¹⁵

Visual Aid: Components of the TriGrid System

Component	Description	Function
Pulse Stimulator	The base unit or console housing control software and power electronics.	Generates and controls the precisely defined electrical pulses for the treatment protocol.¹⁵
Integrated Applicator	A reusable, handheld device that interfaces between the stimulator and the cartridge.	Houses the cartridge and automatically deploys the electrodes and initiates the full sequence upon activation.¹⁴, ¹⁵
Application Cartridge	A sterile, single-use, disposable component.	Houses the nucleic acid drug and integrates the proprietary TriGrid electrode array, ensuring safety and consistency.¹⁴, ¹⁵

The proprietary TriGrid electrode array typically consists of four penetrating needle-type electrodes. They are arranged in a pattern of two interlocking equilateral triangles, forming a diamond shape around a central injection needle.⁹, ¹⁷ This configuration ensures the injected drug is distributed within the tissue volume targeted by the electrical field.

Technological Progression: TriGrid 1.0 vs. TriGrid 2.0

Ichor developed the platform through distinct versions. This reflects a clear strategy of refinement aimed at commercialization. The TriGrid® 1.0 was designed for flexibility in early-phase clinical studies. The TriGrid® 2.0 system incorporated key refinements to support large-scale clinical use and commercial deployment.¹⁴, ¹⁸

Feature	TriGrid® 1.0 (Early Phase)	TriGrid® 2.0 (Commercial Grade)
Primary Design Goal	Flexibility for administration conditions in early-phase clinical studies.¹⁴	Optimized for large-scale clinical use and commercial deployment.¹⁸
Drug Format	Designed for standard vial/syringe drug preparation.¹⁴	Compatible with pre-filled syringe format, simplifying drug handling and reducing errors.¹⁵, ¹⁸
Usability	Functional user interface for clinical research settings.¹⁴	Improved interface, usability, and ergonomics for broader clinical adoption.¹⁵, ¹⁸
Operational Setting	Standard clinical research unit setup.¹⁴	Portable configurations (cart-mounted or tabletop) with battery operation for flexible use.¹⁵, ¹⁸
Support Features	Basic operational controls.¹⁴	On-board training, help, and installation modes to support wider and easier deployment.¹⁵, ¹⁸
Regulatory Status	Investigational device for clinical trials.¹⁴	Designed for full compliance with applicable international standards for commercial medical devices.¹⁵, ¹⁸

This evolutionary path demonstrates a strategic progression from a functional prototype to a polished, user-friendly, and regulatory-compliant system.

III. Market and Competitive Positioning

A. Ichor Medical Systems: Corporate Profile

The central player behind TriGrid is Ichor Medical Systems, Inc. It is a privately-held biotechnology company founded in 1994.²⁰, ²³ The company’s headquarters and laboratories are in San Diego, California.¹⁹, ²¹, ²², ²³ It is crucial to distinguish this entity from Ichor Systems (a semiconductor equipment manufacturer) and Ichor Life Sciences (a contract research organization).²⁴, ²⁵, ²⁶, ²⁷, ⁷¹, ⁷², ⁷³, ⁷⁴, ⁷⁵

Ichor’s business model is that of a specialized technology provider. The company provides its proprietary TriGrid platform as an enabling delivery solution for its partners’ nucleic acid-based drugs.¹³, ¹⁶ Its revenue model is structured around platform licensing agreements. These include upfront payments, development milestones, and potential royalties on sales of commercialized products that use the TriGrid system.²⁸, ⁴⁵

Ichor has established a portfolio of collaborations with a diverse range of partners. These include major pharmaceutical companies like Pfizer and Janssen Pharmaceuticals, biotechnology firms such as Scancell Holdings, and U.S. government agencies like DARPA and the Naval Medical Research Center.¹⁰, ¹³, ¹⁶, ²⁹, ⁴⁵, ⁵¹ These collaborations cover a wide array of disease indications, including oncology, chronic viral infections, and biodefense applications.¹³, ⁵¹

B. The Clinical Electroporation Landscape

Ichor Medical Systems operates in a specialized but competitive niche. The primary competitor to Ichor’s TriGrid is Inovio Pharmaceuticals and its CELLECTRA® family of devices.⁹

A key strategic differentiator is the business model. Ichor is a pure-play platform company licensing its technology to external partners. In contrast, Inovio is an integrated biopharmaceutical company. It primarily develops its own pipeline of DNA medicines using its proprietary devices.

Table 1: Comparative Analysis of Clinical-Stage Electroporation Platforms

Feature	TriGrid® Delivery System	CELLECTRA®
Company	Ichor Medical Systems, Inc.	Inovio Pharmaceuticals, Inc.
Company Profile	Private, San Diego, CA	Public (NASDAQ: INO), Plymouth Meeting, PA
Key Design Feature	Fully integrated and automated single-button administration of drug and electrical pulse.⁹, ¹⁴, ¹⁵, ¹⁶	Handheld applicator device, often used following a separate injection step.
Primary Target Tissues	Skeletal muscle and skin.¹, ⁹	Intramuscular and intradermal delivery.
Business Model	Technology platform licensor; enables partners’ drug pipelines.¹³, ¹⁶	Integrated model; primarily develops its own DNA medicines delivered by its proprietary device.
Notable Public Partners	Pfizer, Janssen, Scancell, DARPA, Naval Medical Research Center.¹⁶, ²⁹, ⁵¹	Regeneron, various global health organizations (e.g., CEPI), primarily for its own pipeline.

C. Broader Context: Alternative Nucleic Acid Delivery Modalities

Electroporation is one of several competing approaches for the in vivo delivery of nucleic acids.⁹ Key alternative modalities include:

Gene Gun (Biolistic Particle Delivery): Uses high-pressure gas to propel DNA-coated microscopic particles into skin cells.⁶, ⁷⁶
Needle-Free Injection Systems (NFIS): Use a high-pressure fluid stream to deliver a drug payload into tissue.⁶⁸
Lipid Nanoparticles (LNPs): A chemical delivery method where nucleic acids (most famously, mRNA) are encapsulated within a sphere of lipids. This technology was the cornerstone of the Pfizer-BioNTech and Moderna COVID-19 vaccines.³⁰, ³¹, ⁷⁷
Viral Vectors: Uses modified, non-pathogenic viruses (such as AAV) as vehicles to carry genetic material into cells, a common method for gene therapy.⁶⁸, ⁷⁸

The choice of delivery strategy depends on the specific nucleic acid, target tissue, and disease indication. TriGrid’s competitive position is defined by its ability to offer a compelling combination of efficiency, safety, and reproducibility for DNA and RNA delivered to muscle or skin.

IV. Strengths and Market Opportunities

This section highlights the distinct advantages of the TriGrid technology and the market opportunities it is positioned to address.

A. Core Strengths of the TriGrid Platform

Dramatically Enhanced Potency: The fundamental strength of the TriGrid system is its proven ability to increase the potency of nucleic acid therapeutics by 10 to 1,000-fold compared to conventional injection.⁹
Reproducibility and Standardization: The platform’s integration and automation remove operator variability, ensuring a consistent procedure essential for regulatory approval and commercial scaling.⁹, ¹⁴, ¹⁵
Favorable Safety Profile: Across multiple clinical trials, the TriGrid system has demonstrated a tolerable safety profile. Most adverse events are mild, transient, and localized to the injection site.¹⁰, ³⁸
Strong Intellectual Property: Ichor holds multiple patents covering its innovative solutions for nucleic acid delivery. These patents protect device configurations, electroporation methods, and specific apparatus designs, creating a strong competitive moat.¹⁶, ⁴⁷, ⁴⁸

B. Market Opportunities

Expanding Nucleic Acid Pipelines: The fields of gene therapy, DNA vaccines, and DNA-encoded antibodies are rapidly expanding.⁹ Many of these novel candidates will require an advanced delivery system, creating sustained demand for technologies like TriGrid.
Oncology and Infectious Diseases: TriGrid is well-positioned to serve two of the largest areas of biopharmaceutical R&D. Its ability to generate robust T-cell responses is particularly valuable for therapeutic cancer vaccines and for vaccines against complex pathogens.¹, ¹⁰, ¹³, ⁴⁵, ⁵¹, ⁶³
Platform Business Model: Ichor’s licensing strategy allows it to participate in the upside of numerous therapeutic programs without bearing the full cost and risk of drug development.
Biodefense and Rapid Response: DNA vaccines are often more temperature-stable than other vaccine types, a key logistical advantage for stockpiling. TriGrid’s reproducibility and ease of use mean that minimally trained personnel could administer a countermeasure consistently during a crisis. This is a critical requirement for agencies like DARPA, which has funded Ichor’s work.¹⁰, ¹⁶, ²⁹

V. The Pfizer Collaboration: A Strategic Dissection

A. Timeline and Terms of the 2014 Agreement

Ichor Medical Systems and Pfizer Inc. publicly announced their Collaboration and License Agreement on February 5, 2014.¹⁰, ¹⁷, ²⁹, ⁴⁵ The objective was for Ichor to develop its next-generation TriGrid devices. These devices would be used to facilitate the clinical administration of DNA-based vaccines as part of Pfizer’s preclinical cancer vaccine-based immunotherapy research program.¹³, ⁴⁵

Under the agreement, Ichor would receive an upfront payment, future development milestone payments, and royalty payments on potential future sales.²⁸, ⁴⁵ The two parties agreed to share initial development expenditures. Pfizer would later assume full responsibility for manufacturing and commercialization.⁴⁵

Visual Aid: Timeline of Key Events

Date	Event	Significance
Feb 5, 2014	Ichor and Pfizer announce their Collaboration and License Agreement for DNA-based cancer vaccines.²⁹, ⁴⁵	This served as a major validation of TriGrid technology by a leading pharmaceutical company to enable its immuno-oncology pipeline.
2018	Pfizer partners with BioNTech to develop an mRNA-based influenza vaccine.³⁰	This marks Pfizer’s strategic investment and pivot towards the emerging mRNA-LNP platform technology.
2020	Pfizer and BioNTech rapidly develop and launch the Comirnaty COVID-19 vaccine.³⁰, ³⁵	The unprecedented success of the mRNA-LNP platform solidifies it as Pfizer’s core vaccine technology, likely leading to the deprioritization of its earlier DNA-based programs.

B. Pfizer’s Rationale: Why TriGrid?

Pfizer’s decision to license TriGrid in 2014 was a calculated move. The company’s 2014 Annual Report shows a strategic goal of building an industry-leading program in immuno-oncology.³⁴ Therapeutic cancer vaccines were a promising modality. However, Pfizer was aware of the low potency of its DNA-based candidates when delivered conventionally.⁹, ⁶⁸

Ichor’s TriGrid system presented a turnkey solution to de-risk this high-priority R&D segment. By licensing a clinically-tested, automated platform, Pfizer acquired a best-in-class delivery capability it did not possess internally. This increased the probability of success for its proprietary DNA vaccine assets. James Merson, then a senior R&D executive at Pfizer, confirmed this rationale.¹³, ¹⁷, ⁴⁵

C. Post-Agreement Status and the Shift to mRNA

No major commercial cancer vaccine product has emerged from the Pfizer-Ichor collaboration. This outcome is likely not a reflection of any failure of the TriGrid technology. Instead, it is a consequence of a broader technological and strategic pivot within Pfizer and the industry.

The years following 2014 saw the meteoric rise of messenger RNA (mRNA) technology. This was coupled with lipid nanoparticle (LNP) delivery systems, which emerged as a more potent and versatile platform.³¹, ³⁶, ⁸² Pfizer’s pivotal 2018 partnership with BioNTech to develop an mRNA flu vaccine gave it access to this cutting-edge platform.³⁰

The historic success of their subsequent COVID-19 vaccine, Comirnaty, fundamentally reshaped Pfizer’s vaccine strategy.³⁰, ³⁵ BioNTech itself had been working on personalized mRNA cancer vaccines since 2014, demonstrating the technology’s maturity.³⁷

It is highly probable that Pfizer’s internal DNA-based cancer vaccine programs were strategically deprioritized. This happened as the superior potency and manufacturing speed of the mRNA-LNP platform became evident. The Ichor-Pfizer agreement was for a specific purpose: to deliver DNA-based cancer vaccines. When the underlying therapeutic modality (DNA) was superseded by a more advanced one (mRNA) within Pfizer’s strategy, the associated delivery device became obsolete for that partner and purpose.

VI. Critical Assessment of TriGrid’s Performance and Limitations

A. Evidence from the Field: Clinical Trial Analysis

An objective assessment of TriGrid’s performance requires analyzing clinical trial data. The most comprehensive public evidence comes from Ichor’s partnership with Scancell Holdings plc for their DNA ImmunoBody® vaccine, SCIB1, for melanoma.

The initial Phase 1/2 clinical trial (NCT01138410), with results published in 2018, provided strong early signals. The trial found that the SCIB1 vaccine, delivered via TriGrid, successfully stimulated the immune system in approximately 88% of evaluable patients.³⁸ The safety profile was favorable, with most side effects being mild and related to the injection site.¹⁰, ³⁸

More compelling evidence comes from the subsequent Phase 2 SCOPE trial (NCT04079166). This trial evaluated SCIB1 and a next-generation version, iSCIB1+, in combination with standard-of-care checkpoint inhibitors.⁴⁰, ⁴¹, ⁶⁵ The data, presented in 2024 and 2025, were highly positive.⁴⁰, ⁶⁵

Visual Aid: Key Efficacy Results from the SCOPE Trial

Metric	SCIB1/iSCIB1+ with Checkpoint Inhibitors	Historical Benchmark (Checkpoint Inhibitors Alone)
Overall Response Rate (ORR)	68.6% ⁴⁰, ⁸³, ⁸⁴	~48-50% ⁴⁰, ⁶⁵, ⁸⁵
12-month Progression-Free Survival (PFS)	64.6% (Cohort 1) ⁴⁰, ⁸³, ⁸⁴	43.9% ⁴⁰

Crucially, the safety data from the SCOPE trial were also positive. The addition of the TriGrid-delivered vaccine did not introduce any new or meaningful toxicity over that expected from the checkpoint inhibitor regimen alone.⁴⁰, ⁴², ⁷⁹, ⁸⁴ This clinical evidence strongly supports the conclusion that the TriGrid technology performs its intended function effectively and safely.

B. General Limitations of the Electroporation Modality

While effective, electroporation as a delivery method has inherent limitations.

Tissue Accessibility: Electroporation is most effective for accessible tissues like skin and muscle.⁹ Delivering agents to deep-seated organs requires invasive procedures, limiting its applicability compared to systemic methods like LNPs.⁷
Patient Discomfort: The application of electrical pulses is inherently associated with sensation or pain at the administration site.³⁸ While generally mild, this can be a barrier to patient compliance, especially for therapies requiring frequent dosing.
Potential for Localized Tissue Damage: The electric field must be carefully controlled to induce reversible electroporation. If parameters are not optimized, there is a risk of causing irreversible damage, leading to localized cell necrosis or thermal injury.⁶⁸, ⁷⁰
Regulatory and Logistical Complexity: An electroporation-based therapy is regulated as a “Combination Product” by the FDA. This can involve more onerous requirements for design, testing, and documentation than for a drug alone.⁷⁰ It also adds logistical complexity, requiring specialized hardware and operator training.

C. Identifying Potential Weaknesses of TriGrid

Beyond the general limitations of the modality, a critical analysis must consider weaknesses specific to the TriGrid technology.

The most direct evidence of a limitation comes from the peer-reviewed summary of the initial Scancell Phase 1/2 trial. The report states that one patient, out of 35, stopped treatment because they found the short electrical pulse to be “too uncomfortable”.³⁸ While a single data point, it confirms that tolerability can be an issue for a subset of patients.

A second, strategic weakness is the platform dependency risk. Ichor’s success is entirely contingent on the clinical and commercial success of its partners’ therapeutic products. If a partner’s drug fails in a late-stage trial, Ichor receives no milestone or royalty payments. The history of biotechnology is filled with examples of companies whose value was decimated by a single trial failure. For instance, Cantab Pharmaceuticals’ share price plunged 67% after one trial failure, illustrating the unforgiving market environment.⁸⁶

Finally, the technology faces a significant risk of technological obsolescence. The biopharmaceutical landscape is characterized by rapid innovation. As the Pfizer collaboration demonstrated, the rise of a superior platform can cause a strategic pivot that renders a previously valuable technology less relevant.

VII. Investigation into Potential Cronyism

A direct investigation into potential cronyism in the 2014 Pfizer-Ichor agreement requires examining the corporate governance of both companies at the time. This involves comparing the executive leadership and boards of directors for both companies during the 2013-2014 period to identify any material overlaps.

Ichor Medical Systems Leadership (circa 2014):

Robert “Bob” Bernard: Co-Founder, President & CEO.¹⁹³, ²⁰⁰
Jeff Walker: Co-Founder.¹⁹³

Pfizer Inc. Leadership and Board of Directors (2014):

Executive Leadership Team: Key leaders included Ian C. Read (Chairman and CEO), Mikael Dolsten, M.D., Ph.D. (President, Worldwide R&D), Albert Bourla, D.V.M., Ph.D. (Group President), and James Merson (SVP and CSO of Vaccine Immunotherapeutics).³⁴, ⁴⁵, ⁴⁶, ⁴⁷, ⁸⁷, ⁸⁸
Board of Directors (2014): The board included Dennis A. Ausiello, W. Don Cornwell, Frances D. Fergusson, Helen H. Hobbs, Constance J. Horner, James M. Kilts, George A. Lorch, Shantanu Narayen, Suzanne Nora Johnson, Ian C. Read, Stephen W. Sanger, James C. Smith, and Marc Tessier-Lavigne.⁴⁸, ⁴⁹, ⁸⁹

Analysis and Conclusion:

A systematic cross-reference of individuals from both organizations reveals no evidence of overlap or pre-existing corporate governance connections. The absence of such connections strongly suggests the collaboration resulted from a standard, arm’s-length business development process. The deal’s logic was driven by strategic and technological considerations, not personal influence.

VIII. Risk Analysis and Future Outlook

A. Contingency Assessment: The Impact of Underperformance

It is essential to consider the consequences if Ichor’s TriGrid technology were to underperform. For Ichor Medical Systems, the impact would be severe. As a private company whose valuation depends almost entirely on its core TriGrid platform, a major technological or clinical setback would critically undermine its ability to secure future partnerships and continue operations.

For Ichor’s pharmaceutical and biotech partners, a failure of the TriGrid delivery system would represent a major and costly setback. It would jeopardize the development of their specific drug candidate. This would force them to either attempt a costly reformulation with a different delivery system or abandon the drug candidate altogether.

B. Backup Plans and The Broader Market

While a TriGrid platform failure would be significant for the companies involved, the broader biopharmaceutical field has inherent backup plans. The industry operates on a principle of parallel development, with multiple delivery modalities being advanced simultaneously. Should TriGrid prove to be a dead end, the industry would intensify its focus on other platforms, including:⁶, ⁶⁸, ⁷⁶, ⁷⁸

Lipid Nanoparticles (LNPs): Already the dominant technology for mRNA delivery.
Viral Vectors (e.g., AAV): A mature and highly efficient technology for gene therapy.
Alternative Physical Methods: Technologies like gene guns and needle-free injection systems.
Competing Electroporation Devices: A failure of TriGrid would not necessarily invalidate the entire principle of electroporation. Partners could potentially turn to competing devices, such as Inovio’s CELLECTRA®.

From Ichor’s perspective, its own backup plan is its portfolio strategy. The company mitigates risk by establishing partnerships with multiple companies across a range of different disease indications.¹⁶, ²⁹, ⁵¹ The failure of any single partner’s drug program does not spell failure for the platform as a whole.

C. Strategic Recommendations and Concluding Analysis

Ichor Medical Systems’ TriGrid Delivery System is a mature and clinically-validated enabling technology. It has successfully addressed a critical engineering challenge for the in vivo delivery of nucleic acid therapeutics. The platform’s performance, particularly in Scancell’s melanoma vaccine trials, provides strong proof-of-concept for its ability to safely enhance the potency of DNA-based immunotherapies.

The primary uncertainty surrounding TriGrid is commercial, not technological. Its future is linked to the success of its partners’ pipelines and its ability to compete with alternative delivery technologies.

Recommendations for Future Strategy:

Diversify Partnerships: Continue to build a broad portfolio of partners across different therapeutic areas and stages of development to mitigate single-program failure risk.
Target Niche Applications: Focus on therapeutic areas where electroporation offers a distinct advantage over LNPs or viral vectors. This includes therapeutic cancer vaccines for accessible tumors (e.g., melanoma) where generating a strong, localized T-cell response is paramount. It also includes DNA-based therapies for chronic viral infections (e.g., Hepatitis B) where stable, repeatable intramuscular dosing is a key requirement.¹, ¹⁰, ¹³, ⁴⁵, ⁵¹
Highlight Clinical Data: Proactively use the strong efficacy and safety data from trials like SCOPE to market the platform’s reliability and clinical validation to potential new partners.
Explore Next-Generation Payloads: Actively partner with companies developing novel nucleic acid constructs beyond standard DNA vaccines. Examples include DNA-encoded monoclonal antibodies (dMAbs) or self-amplifying DNA, which would keep the platform at the forefront of innovation.¹, ⁹

In conclusion, Ichor Medical Systems represents a classic high-risk, high-reward investment in an enabling technology platform. The fundamental device functions as designed and has a favorable safety profile. Therefore, any future due diligence should focus less on the device’s core mechanism. Instead, it should focus on the scientific merit of its partners’ therapeutic candidates and the competitive positioning of electroporation within those specific disease indications.

IX. Glossary of Key Terms

Electroporation: A technique in which an electrical field is applied to cells to increase the permeability of the cell membrane, allowing molecules like DNA to enter the cell.¹, ³, ⁴, ⁵, ⁷, ¹¹, ¹³, ⁴⁵
Lipid Nanoparticles (LNPs): A delivery vehicle where nucleic acids (like mRNA) are encapsulated within a tiny sphere of specialized lipids, which can fuse with cell membranes to release their genetic payload.³⁰, ³¹, ⁷⁷
Nucleic Acid Therapeutics: A class of drugs based on DNA or RNA that work by modulating the expression of genes to treat diseases.¹
Overall Response Rate (ORR): In oncology, the proportion of patients in a trial whose tumor is destroyed or significantly shrinks after treatment.⁴⁰, ⁴², ⁷⁹, ⁸³, ⁸⁴, ⁸⁵, ⁹⁰
Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with a disease, but it does not get worse.⁴⁰, ⁸³, ⁸⁴
Viral Vector: A tool that uses a modified, non-pathogenic virus to deliver genetic material into cells.⁶⁸, ⁷⁸

Works Cited

Keane-Myers, A., Bell, M., Hannaman, D., & Albrecht, M. “DNA Electroporation of Multi-agent Vaccines Conferring Protection Against Select Agent Challenge: TriGrid Delivery System.” Springer Nature Experiments. https://experiments.springernature.com/articles/10.1007/978-1-4614-9632-8_29
Zarzycki, C., Levy, M., Jablonowski, C., & Overfelt, J. “An Evaluation of a Variable-Resolution GCM for Climate Simulation in the Contiguous United States.” Journal of Climate. April 2015. https://journals.ametsoc.org/view/journals/clim/28/7/jcli-d-14-00599.1.pdf
Rolong, A., & Davalos, R. “History of Electroporation.” Semantics Scholar. 2017. https://www.semanticscholar.org/paper/History-of-Electroporation-Rolong-Davalos/3ab22b0144f5429c45e8c8423270c2174ed967ea
Cancer Research UK. “A trial of SCIB1 injections for melanoma.” https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-scib1-injections-for-melanoma
Wikipedia. “Electroporation.” https://en.wikipedia.org/wiki/Electroporation
U.S. Department of Energy Office of Scientific and Technical Information. “Energy Exascale Earth System Model (E3SM) Project Version 2.1.” January 12, 2023. https://www.osti.gov/doecode/biblio/98639
Šersa, G., et al. “In vivo electroporation of tumors.” Frontiers in Bioengineering and Biotechnology. December 2022. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.1094968/full
Mayo Clinic. “History of COVID-19: Outbreaks and vaccine timeline.” https://www.mayoclinic.org/diseases-conditions/history-disease-outbreaks-vaccine-timeline/covid-19
Hannaman, D., et al. “Electroporation Based TriGrid Delivery System (TDS) for DNA Vaccine Administration.” ResearchGate. 2012. https://www.researchgate.net/publication/227157948_Electroporation_Based_TriGrid_Delivery_System_TDS_for_DNA_Vaccine_Administration
Pfizer. “The Facts.” January 29, 2024. https://www.pfizer.com/about/responsibility/misinformation
Infection Control Today. “Florida Surgeon General Raises Concerns Over DNA Contaminants in Pfizer and Moderna COVID-19 Vaccines.” January 8, 2024. https://www.infectioncontroltoday.com/view/florida-surgeon-general-raises-concerns-over-dna-contaminants-pfizer-and-moderna-covid-19-vaccines
Pfizer. “Pfizer Board of Directors 2014.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/letter_directors.htm
Pfizer. “Ichor Enters Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens.” February 5, 2014. https://www.pfizer.com/print/pdf/node/555531
Ichor Medical Systems. “TriGrid® 1.0.” https://ichorms.com/early-phase/
Ichor Medical Systems. “TRIGRID® DEVICES.” https://ichorms.com/trigrid-devices/
Ichor Medical Systems. “Patents.” https://ichorms.com/patents-2/
FiercePharma. “Pfizer snags electroporation device license from Ichor for cancer vaccine delivery.” February 5, 2014. https://www.fiercepharma.com/partnering/pfizer-snags-electroporation-device-license-from-ichor-for-cancer-vaccine-delivery
Ichor Medical Systems. “TRIGRID® 2.0.” https://ichorms.com/commercial/
Scancell. “Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+.” July 22, 2025. https://scancell.co.uk/wp-content/uploads/2025/07/20250722-SCOPE-Data_Press-Release-PL.pdf
Tracxn. “Ichor Medical Systems.” https://tracxn.com/d/companies/ichor-medical-systems/__skImLuSQtLXQKmmmsjjTb6BquG0vaQnfLuJAORtM6LM
Bionity. “Ichor Medical Systems, Inc. – San Diego, USA.” https://www.bionity.com/en/companies/16811/ichor-medical-systems-inc.html
PitchBook. “Ichor Medical Systems.” https://pitchbook.com/profiles/company/331161-76
Biotech Careers. “Ichor Medical Systems.” https://www.biotech-careers.org/company/ichor-medical-systems
Ichor Systems. “Locations.” https://www.ichorsystems.com/locations
Ichor Life Sciences. “About Our Company.” https://ichorlifesciences.com/about/
Comparably. “Ichor Systems Executive Team.” https://www.comparably.com/companies/ichor-systems/executive-team
The Org. “Ichor Systems – Leadership Team.” https://theorg.com/org/ichor-systems/teams/leadership-team
FirstWord HealthTech. “Ichor Medical Systems, Pfizer ink collaboration agreement.” February 5, 2014. https://firstwordhealthtech.com/story/1086955
Ichor Medical Systems. “Press Releases.” https://ichorms.com/press-releases-2/
Wikipedia. “Pfizer–BioNTech COVID-19 vaccine.” https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine
Yale Medicine. “COVID-19 Vaccine Comparison: What to Know About the 2024-2025 Shots.” https://www.yalemedicine.org/news/covid-19-vaccine-comparison
Mayo Clinic. “COVID-19 vaccines for kids: What you need to know.” https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/covid-19-vaccines-for-kids/art-20513332
Mayo Clinic. “What are the different types of COVID-19 vaccines?” https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/different-types-of-covid-19-vaccines/art-20506465
Pfizer. “2014 Annual Report.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/assets/pdfs/pfi2014ar_ceo_all.pdf
PMC. “mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation.” January 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9864138/
Pfizer. “mRNA and Artificial Intelligence for Advanced Vaccine Innovation.” https://www.pfizer.com/news/articles/how_a_novel_incubation_sandbox_helped_speed_up_data_analysis_in_pfizer_s_covid_19_vaccine_trial
Cancer Research Institute. “COVID-19 and Cancer Vaccines with Immunotherapy Pioneers Ugur Sahin and Özlem Türeci.” 2021. https://www.cancerresearch.org/blog/mrna-covid-cancer-vaccines-ugur-sahin-ozlem-tureci
Cancer Research UK. “A trial of SCIB1 injections for melanoma.” 2018. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-scib1-injections-for-melanoma
ResearchGate. “Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.” May 2021. https://www.researchgate.net/publication/351132897_Neutralizing_monoclonal_antibodies_present_new_prospects_to_treat_SARS-CoV-2_infections
Scancell. “Active Immunotherapy for a Cancer-Free Future.” July 22, 2025. https://scancell.co.uk/wp-content/uploads/2025/07/Scancell-iSCIB1-strongly-improved-outcomes-in-Late-Stage-Melanoma-SCOPE-study-results.pdf
ClinicalTrials.gov. “SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study).” April 4, 2025. https://clinicaltrials.gov/study/NCT04079166
ASCO. “A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.” 2023. https://www.asco.org/abstracts-presentations/ABSTRACT450020
HistoryOfVaccines.org. “The History of the mRNA Vaccines.” January 3, 2021. https://historyofvaccines.org/blog/the-history-of-the-mrna-vaccines/
Ichor Medical Systems. “TEAM.” https://ichorms.com/team/#:~:text=Robert%20Bernard%2C%20President%20%26%20CEO&text=He%20is%20a%20proven%20entrepreneur,and%20manages%20Ichor’s%20commercial%20partnerships.
Pfizer. “Ichor Enters Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens.” February 5, 2014. https://www.pfizer.com/news/press-release/press-release-detail/ichor-enters-agreement-pfizer-develop-electroporation
Pfizer. “Executive Leadership Team 2014.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/assets/pdfs/pfi2014ar_ceo_elt.pdf
Bullfincher.io. “Pfizer Org chart.” https://bullfincher.io/companies/pfizer/org-chart
Pfizer. “Board of Directors 2014.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/assets/pdfs/pfi2014ar_ceo_board.pdf
Pfizer Limited. “Pfizer Limited Annual Report 2014-15.” 2015. https://www.pfizerltd.co.in/files/pfizer_limited_annual_report_2014_15-3.pdf
Ichor Life Sciences. “Clinical Trial Services.” https://ichorlifesciences.com/clinical-trial-services/
Ichor Medical Systems. “Clinical.” https://ichorms.com/782-2-2/
BioSpace. “Ichor Medical Systems Announces Utilization of Its Investigational TriGrid Delivery System in a Clinical Trial…” August 21, 2018. https://www.biospace.com/ichor-medical-systems-announces-utilization-of-its-investigational-trigrid-delivery-system-in-a-clinical-trial-evaluating-gx-188e-vaccine-combined-with-a-checkpoint-inhibitor-for-treatment-of-cervical-cancer
BioSpace. “FDA Approves Phase I Clinical Trial Using Ichor Medical Systems, Inc.’s TriGrid System…” May 14, 2007. https://www.biospace.com/fda-approves-phase-i-clinical-trial-using-ichor-medical-systems-inc-s-trigrid-system-and-dna-vaccine-for-melanoma-developed-at-sloan-kettering
Ichor Life Sciences. “Leadership Team.” https://ichorlifesciences.com/our-team/
EE Times. “Ichor Medical Partners With Flextronics.” May 7, 2014. https://www.eetimes.com/ichor-medical-partners-flextronics/
Pfizer. “Understanding Six Types of Vaccine Technologies.” https://www.pfizer.com/news/articles/understanding_six_types_of_vaccine_technologies
JITC. “1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab…” October 31, 2023. https://jitc.bmj.com/content/11/Suppl_2/A1756
Trinity Delta. “SCOPE’ing out iSCIB1+ in advanced melanoma.” August 4, 2025. https://www.trinitydelta.org/research-notes/scopeing-out-iscib1-in-advanced-melanoma/
Clinical Trial Vanguard. “Scancell’s Phase 2 Data Shows Improved Outcomes in Late-Stage Melanoma.” July 23, 2025. https://www.clinicaltrialvanguard.com/news/scancells-phase-2-data-shows-improved-outcomes-in-late-stage-melanoma/
Pfizer. “Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts.” January 15, 2020. https://www.pfizer.com/pfizer-brings-three-new-biosimilars-us-patients-substantial-discounts
Minnetronix Medical. “Difficulties of Electromechanical Devices for In Vivo Electroporation.” https://minnetronixmedical.com/difficulties-of-electromechanical-devices-for-in-vivo-electroporation/
ResearchGate. “History of Electroporation.” 2017. https://www.researchgate.net/publication/322092564_History_of_Electroporation
FirstWord Pharma. “Ichor Partner Scancell Announces Update on SCIB1 Phase 1/2…” June 2, 2015. https://firstwordpharma.com/story/2726405
Global Vaccine Data Network. “Plasmid-gate: Debunking the DNA contamination claims in mRNA vaccines.” October 17, 2024. https://www.globalvaccinedatanetwork.org/news/plasmid-gate_debunking_the_DNA_contamination_claims_in_mRNA_vaccines
larvol clin. “SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study).” https://clin.larvol.com/trial-detail/NCT04079166
Davidson College. “Electroporation.” 2003. https://www.bio.davidson.edu/Courses/Molbio/MolStudents/spring2003/McCord/electroporation.htm
Springer Nature Experiments. “In Vivo Electrotransfer of Genes into Tissues and Organs.” 2007. https://experiments.springernature.com/articles/10.1007/978-1-59745-194-9_2
PMC. “Gene Delivery to Skeletal Muscle.” June 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6600476/
PMC. “History of electroporation science.” June 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4463294/
Minnetronix Medical. “Difficulties of Electromechanical Devices for In Vivo Electroporation.” https://minnetronixmedical.com/difficulties-of-electromechanical-devices-for-in-vivo-electroporation/
Ichor Holdings. “Board of Directors.” https://ir.ichorsystems.com/websites/ichorholdings/English/4200/board-of-directors.html
Simply Wall St. “Ichor Holdings Management.” https://simplywall.st/stocks/us/semiconductors/nasdaq-ichr/ichor-holdings/management
Ichor Holdings. “Management Team.” https://ir.ichorsystems.com/management-team
US Fed News. “US Patent Issued to ICHOR SYSTEMS on Sept. 9 for ‘Flow control system, method, and apparatus’…” September 10, 2025. https://www.htsyndication.com/us-fed-news/article/us-patent-issued-to-ichor-systems-on-sept.-9-for–flow-control-system%2C-method%2C-and-apparatus—nevada%2C-texas-inventors-/22213947820
Pfizer CentreOne. “Leadership Team.” https://www.pfizercentreone.com/about-us/leadership-team
PMC. “Head-to-head comparison of DNA vaccine delivery by gene gun vs. electroporation to elicit antigen-specific CD8+ T cells.” September 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC2745985/
Labiotech.eu. “5 years later: What happened to COVID vaccine companies?” May 2, 2025. https://www.labiotech.eu/in-depth/covid-vaccine-companies/
MIT DSpace. “In vitro and ex vivo intracellular delivery of pristine nanoparticles.” 2017. https://dspace.mit.edu/bitstream/handle/1721.1/110923/in%20vitro%20and%20ex%20vivo.pdf?sequence=2&isAllowed=y
OncLive. “SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma.” April 22, 2024. https://www.onclive.com/view/scib1-plus-nivolumab-ipilimumab-generates-orr-of-85-in-advanced-unresectable-melanoma
Justia Patents. “Patents Assigned to Ichor Medical Systems, Inc.” https://patents.justia.com/assignee/ichor-medical-systems-inc
Ichor Medical Systems. “Overview.” https://ichorms.com/overview/
The Medicine Maker. “This Week’s Biopharma News: Pfizer, BioNTech, and Moderna Court Case Continues.” July 14, 2025. https://themedicinemaker.com/issues/2025/articles/july/this-week-s-biopharma-news-pfizer-biontech-and-moderna-court-case-continues/
OncLive. “SCIB1/iSCIB1+ Vaccines Plus Checkpoint Inhibition Generate Immune Responses in Advanced Melanoma.” July 22, 2025. https://www.onclive.com/view/scib1-iscib1-vaccines-plus-checkpoint-inhibition-generates-immune-responses-in-advanced-melanoma
Targeted Oncology. “Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma.” September 21, 2023. https://www.targetedonc.com/view/phase-2-scope-trial-of-scib1-achieves-positive-orr-in-advanced-melanoma
PMC. “Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.” April 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11048403/
PMC. “Biotechnology company’s shares dive 67% after drug failure.” October 2000. https://pmc.ncbi.nlm.nih.gov/articles/PMC1118843/
ExecutiveGov. “Pfizer Inc. Leaders, Founders, and Executives: Who Are They?” https://www.executivegov.com/articles/pfizer-inc-leaders-founders-and-executives-who-are-they
Pfizer. “Executive Leadership Team 2014.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/letter_team.htm
Pfizer. “Board of Directors 2014.” 2014. https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2014/letter_directors.htm
PMC. “In Vivo Electroporation-Mediated Gene Delivery to the Heart.” 2011. https://scispace.com/pdf/in-vivo-electroporation-mediated-gene-delivery-to-the-667ucayrqc.pdf

An In-Depth Analysis of Ichor Medical Systems’ TriGrid Electroporation Platform